An update from Oxford BioMedica ( (GB:OXB) ) is now available.
Oxford Biomedica PLC has announced the notice of its Annual General Meeting (AGM) for 2025, which will be held on 11 June at its Oxford offices. The company has made the AGM notice and its 2024 Annual Report available to shareholders and submitted them to the Financial Conduct Authority for public access. This announcement is part of OXB’s ongoing commitment to transparency and stakeholder engagement, reflecting its strategic focus on maintaining strong governance and communication with its investors.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company has 30 years of experience in viral vectors, collaborating with leading pharmaceutical and biotechnology companies to provide expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. OXB’s capabilities range from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise. The company is headquartered in Oxford, UK, with facilities in the UK, France, and the US.
YTD Price Performance: -22.27%
Average Trading Volume: 19,149
Technical Sentiment Signal: Buy
Current Market Cap: $421.7M
For detailed information about OXB stock, go to TipRanks’ Stock Analysis page.